phrykt

Globus Medical Inc (GMED): who owns it and who trades it

As of Nov 16, 2026, GMED insiders reported 13 open-market sales worth $16M and no purchases in the last 12 months, with 3% of the sale value made under pre-set 10b5-1 plans. The largest seller was James R Tobin (Director), with $5.4M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Globus Medical

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors and Congress mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GMED

595 funds and institutions reported GMED shares worth $9.5B at the end of Q2 2026, about 89% of the company. The largest holder is BlackRock, Inc. with 8.0%.

Funds and institutions (13F) 89%Everyone else 11%

10 largest owners, by share of the company

BlackRock, Inc.8.0%
Jupiter Topco LLC6.0%
Vanguard Capital Management LLC3.8%
Vanguard Portfolio Management LLC3.7%
Invesco Ltd.3.2%
Kayne Anderson Rudnick Investment Management LLC3.2%
State Street Corp2.7%
Sculptor Capital LP2.2%
JPMorgan Chase & Co2.0%
Bank of Montreal1.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.81M7.96%$854M+3%
Jupiter Topco LLC8.20M6.04%$648M–
Vanguard Capital Management LLC5.11M3.76%$404M+1%
Vanguard Portfolio Management LLC4.99M3.68%$395M+2%
Invesco Ltd.4.31M3.17%$341M-0%
Kayne Anderson Rudnick Investment Management LLC4.28M3.15%$338M–
State Street Corp3.71M2.74%$294M+3%
Sculptor Capital LP3.00M2.21%$237M-2%
JPMorgan Chase & Co2.74M2.02%$231M–
Bank of Montreal2.43M1.79%$192M+5%
Alliancebernstein L.P.2.38M1.75%$205M+36%
Dimensional Fund Advisors LP2.37M1.75%$187M+34%
Geode Capital Management, LLC2.15M1.59%$170M+2%
Goldman Sachs Group Inc1.78M1.31%$141M+57%
Arrowstreet Capital, Limited Partnership1.72M1.26%$136M+88%
Boston Trust Walden Corp1.57M1.16%$124M+25%
Allspring Global Investments Holdings, LLC1.57M1.16%$119M+267%
Boston Partners1.55M1.15%$123M–
GW&K Investment Management, LLC1.45M1.07%$115M-3%
Geneva Capital Management LLC1.42M1.04%$112M-20%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GMED insiders reported $0 of open-market purchases and $16M of sales. 3% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$16M
13 trades, 7 people
Sales under a 10b5-1 plan
3%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$3.6M$3.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026James R TobinDirectorSale37,662$75.10$2.8MForm 4
Nov 10, 2026James R TobinDirectorSale4,004$75.68$303KForm 4
Nov 4, 2026Ann D RhoadsDirectorSale plan5,000$85.00$425KForm 4
Sep 15, 2026James R TobinDirectorSale30,000$74.58$2.2MForm 4
Aug 18, 2026Stephen T ZarrilliDirectorSale25,000$87.04$2.2MForm 4
Jun 5, 2026David D DavidarDirectorSale25,000$80.76$2MForm 4
Feb 25, 2026Kelly HullerVice presidentSale20,000$94.50$1.9MForm 4
Feb 12, 2026Kelly HullerVice presidentSale10,000$87.67$877KForm 4
Jan 8, 2026Kyle KlineCFOSale3,594$101.10$363KForm 4
Jan 8, 2026Leslie V NorwalkDirectorSale2,000$101.10$202KForm 4
Dec 12, 2025Leslie V NorwalkDirectorSale4,000$88.85$355KForm 4
Dec 1, 2025Kyle KlineCFOSale18,542$90.00$1.7MForm 4
Nov 25, 2025Kelly HullerVice presidentSale7,500$90.00$675KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
James R TobinDirector–$5.4MNov 10, 2026
Kelly HullerSVP, GC, Corporate Secretary–$3.4MFeb 25, 2026
Stephen T ZarrilliDirector–$2.2MAug 18, 2026
Kyle KlineSenior Vice President, CFO–$2MJan 8, 2026
David D DavidarDirector–$2MJun 5, 2026
Leslie V NorwalkDirector–$558KJan 8, 2026
Ann D RhoadsDirector–$425KNov 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GMED short interest

Moderate short interest. 7.0% of GMED shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 177%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.46M GMED shares were sold short, 7.0% of the shares outstanding, up 15.5% from the report before. At the average daily volume of 1.17M shares, buying them all back would take about 8.1 trading days (days to cover).

Shares short, % of all shares

7.04%May 15Oct 307.72%

Days to cover

8.1May 15Oct 309.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.46M7.04%+15%1.17M8.1
Oct 15, 20268.19M6.10%-3%1.50M5.5
Sep 30, 20268.44M6.28%+25%1.64M5.1
Sep 15, 20266.77M5.04%+2%1.47M4.6
Aug 31, 20266.62M4.93%-3%1.01M6.5
Aug 14, 20266.80M5.07%-1%1.72M4.0
Jul 31, 20266.89M5.07%-3%1.41M4.9
Jul 15, 20267.07M5.21%-5%2.02M3.5
Jun 30, 20267.41M5.46%+35%2.08M3.6
Jun 15, 20265.47M4.03%+40%1.60M3.4
May 29, 20263.92M2.89%+15%2.03M1.9
May 15, 20263.41M2.52%+9%2.11M1.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded GMED

Since Nov 17, 2024, 3 members of Congress reported 4 purchases and 3 sales of GMED. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Sep 3, 2026, reported Oct 12, 2026.

Purchases 4Sales 3

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfOct 12, 2026Report
Aug 19, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$15K–$50KSelfSep 10, 2026Report
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Jul 10, 2025Lisa C. McClain (R-MI)Sale$1K–$15KSpouseAug 13, 2025Report
Jun 24, 2025Lisa C. McClain (R-MI)Partial sale$1K–$15KSpouseAug 13, 2025Report
Jun 17, 2025Lisa C. McClain (R-MI)Purchase$1K–$15KSpouseAug 13, 2025Report
Apr 9, 2025Josh Gottheimer (D-NJ)Partial sale$1K–$15KJointMay 14, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Globus Medical company events

Globus Medical filed 7 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026AnnouncementThe Company’s Board of Directors authorized the Company to repurchase an additional $500.0 million of its Class A common stock under its existing share repurchase program. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 4, 2026LeadershipGlobus Medical, Inc. held its 2026 Annual Meeting of Stockholders at which the Company’s stockholders approved an amendment to the Globus Medical, Inc. 2021 Equity Incentive Plan to increase the number of shares authorized thereunder by 1,000,000 (the Plan as amended by the 2021 Equity Incentive… Filing
  4. May 7, 2026ResultsReleased financial results. Filing
  5. Mar 23, 2026LeadershipJohn A. DeFord, Ph.D., a member of the Board of Directors of Globus Medical, Inc., informed the Company of his resignation from the Board effective immediately. Filing
  6. Feb 24, 2026ResultsReleased financial results. Filing
  7. Jan 7, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Globus Medical financials

Famous investors that hold GMED

5 of the 50 well-known investors we track reported holding GMED in their latest 13F filing. The largest position is Jeremy Grantham's, worth $31M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jeremy Grantham · GMOQ3 2026413,407$31M0.1%+1%
Jim Simons · Renaissance TechnologiesQ3 2026404,918$30.3M0.0%+106%
Ray Dalio · Bridgewater AssociatesQ3 2026316,708$23.7M0.1%-10%
Ken Griffin · Citadel AdvisorsQ3 2026114,620$8.6M0.0%New
Israel Englander · Millennium ManagementQ3 202693,519$7M0.0%+224%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named GMED in the last 120 days.

FiledHolderFormStake
Oct 30, 2026Vanguard Capital Management13G/A4.4%
Oct 30, 2026Vanguard Capital Management13G/A4.4%
Oct 27, 2026BlackRock, Inc.13G/A8.0%
Oct 27, 2026BlackRock, Inc.13G/A8.0%

Questions about Globus Medical Inc (GMED) stock

Who owns the most GMED stock?

The largest reported owner of Globus Medical Inc (GMED) is BlackRock, Inc., with 8.0% of the company. In total, 595 funds and institutions reported holding GMED at the end of Q2 2026, together about 89% of the shares. See the largest owners.

Are GMED insiders buying or selling?

In the last 12 months, GMED insiders reported no open-market purchases and 13 sales worth $16M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in GMED?

As of Oct 30, 2026, 9.46M GMED shares were sold short, 7.0% of the shares outstanding, up 15.5% from the report before. At the average daily volume of 1.17M shares, buying them all back would take about 8.1 trading days (days to cover). See the history.

Have members of Congress traded GMED?

Yes. 3 members of Congress reported 4 purchases and 3 sales of GMED since Nov 17, 2024. The latest was reported on Oct 12, 2026. See the trades.

Which famous investors hold GMED?

5 of the 50 well-known investors we track reported GMED in their latest 13F filing, including Jeremy Grantham, Jim Simons, Ray Dalio. The largest position is worth $31M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.